Global Protein Assays Market

1 INTRODUCTION OF GLOBAL PROTEIN ASSAYSMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PROTEIN ASSAYSMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL PROTEIN ASSAYS MARKET, BY END USER
5.1 Pharmaceutical and Biotechnology Companies
5.2 Clinical Laboratories
5.3 Hospitals
5.4 Academic Research Institutes
5.5 Other End Users

6 GLOBAL PROTEIN ASSAYS MARKET, BY APPLICATION
6.1 Drug Discovery & Development
6.2 Disease Diagnosis
6.3 Other Applications

7 GLOBAL PROTEIN ASSAYS MARKET, BY TECHNOLOGY
7.1 Absorbance-Based Protein Assays
7.2 Colorimetric Protein Assays
7.3 Fluorescence-Based Protein Assays

8 GLOBAL PROTEIN ASSAYS MARKET, BY PRODUCT
8.1 Reagents
8.2 Kits
8.3 Instruments and Accessories

9 GLOBAL PROTEIN ASSAYS MARKET, BY TYPE
9.1 Dye-Binding Assays
9.2 Copper-Ion-Based Assays
9.3 Test Strip-Based Assays
9.4 Other Protein Assays

10 GLOBAL PROTEIN ASSAYSMARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

11 GLOBAL PROTEIN ASSAYSMARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies

12 COMPANY PROFILES
12.1 Bio-Rad Laboratories, Inc.
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments

12.2 Thermo Fisher Scientific Inc.
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments

12.3 Merck KGaA
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments

12.4 Promega Corporation
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments

12.5 GE Healthcare
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments

12.6 Perkinelmer, Inc.
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments

12.7 Geno Technology, Inc.
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments

12.8 Cell Signaling Technology, Inc.
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments

12.9 Abcam PLC.
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Developments

12.10 Novus Biologicals, LLC
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Developments

12.11 Soltec Ventures (Soltec Bio Science)
12.11.1 Overview
12.11.2 Financial Performance
12.11.3 Product Outlook
12.11.4 Key Developments

12.12 Lonza Group
12.12.1 Overview
12.12.2 Financial Performance
12.12.3 Product Outlook
12.12.4 Key Developments

12.13 Biovision Inc.
12.13.1 Overview
12.13.2 Financial Performance
12.13.3 Product Outlook
12.13.4 Key Developments

13 Appendix
13.1 Related Reports